Coronary microcirculatory dysfunction in hypercholesterolemic patients with COVID-19: potential benefit from cholesterol-lowering treatment
In: Annals of Medicine, Jg. 55 (2023-12-01), Heft 1
Online
academicJournal
Zugriff:
AbstractPatients with hypercholesterolemia often have coronary microvascular dysfunction (CMD). Viral infections, such as the SARS-CoV-2 infection, may also result in CMD. Three non-randomized studies have shown significant beneficial effects of statins on CMD in non-infected patients. Similarly, in SARS-CoV-2 - infected patients one beneficial mechanism of action of statins may be the amelioration of endothelial dysfunction, which is a major driver of CMD. Apart from statins, lipoprotein apheresis and PCSK9 inhibitors can also improve or even reverse CMD. The potential reversal of CMD by using effective cholesterol-lowering medications during and after COVID-19 infection, especially in hypercholesterolemic COVID-19 patients, is important.KEY MESSAGESCoronary microvascular dysfunction (CMD) is common in patients hospitalized with SARS-CoV-2 infectionThree nonrandomized studies in non-infected patients are showing the beneficial effects of statin treatment on CMDEffective cholesterol-lowering medication during and after SARS-CoV-2 infection, especially in hypercholesterolemic COVID-19 patients, is of great significance
Titel: |
Coronary microcirculatory dysfunction in hypercholesterolemic patients with COVID-19: potential benefit from cholesterol-lowering treatment
|
---|---|
Autor/in / Beteiligte Person: | Vuorio, Alpo ; Kovanen, Petri T. ; Raal, Frederick J. |
Link: | |
Zeitschrift: | Annals of Medicine, Jg. 55 (2023-12-01), Heft 1 |
Veröffentlichung: | Taylor & Francis Group, 2023 |
Medientyp: | academicJournal |
ISSN: | 0785-3890 (print) ; 1365-2060 (print) |
DOI: | 10.1080/07853890.2023.2199218 |
Schlagwort: |
|
Sonstiges: |
|